Hypothesis

Aged B cells show reduced insulin receptor signaling, leading to sustained nuclear FOXO1 activity that blocks AID transcription and recruitment to immunoglobulin loci, thereby lowering somatic hypermutation (SHM) and class‑switch recombination (CSR). The resulting low‑affinity, poorly sialylated IgG amplifies inflammaging through REST/NF‑κB activation. Restoring insulin signaling in B cells should rescue AID function, improve SHM quality, and normalize IgG glycosylation, extending healthspan.

Mechanistic rationale

• Insulin signaling normally phosphorylates FOXO1, excluding it from the nucleus and permitting E2A/E47‑driven AID transcription.
• In aging, hematopoietic stem cell myeloid bias and low IL‑7 reduce naïve B‑cell output, while chronic inflammation elevates serine kinases (e.g., mTORC1/S6K) that cause insulin receptor substrate‑1 (IRS‑1) serine phosphorylation, attenuating downstream AKT signaling.
• Consequently, FOXO1 remains dephosphorylated, binds the AID promoter, and recruits HDAC complexes that suppress transcription, compounding the noted E47 mRNA instability.
• Reduced AID activity diminishes both SHM and CSR, yielding antibodies with fewer replacement mutations in CDR/framework and altered Fc glycosylation (less sialylation) due to impaired B‑cell cytokine milieu (e.g., lower IL‑21, higher BAFF) that skews Golgi enzymes.
• Pro‑inflammatory IgG engages FcγRIIb on macrophages and dendritic cells, activating REST/NF‑κB pathways that further inhibit insulin signaling in a feed‑forward loop, linking B‑cell dysfunction to T‑cell immunosenescence.

Testable predictions

1. Phospho‑FOXO1 levels in sorted naïve B cells from young vs. old mice will inversely correlate with AID mRNA and SHM frequency (measured by Sanger sequencing of IgVH junctions).
   • Prediction: Old B cells show >2‑fold higher nuclear FOXO1 and <50 % AID transcripts.
2. B‑cell‑specific insulin receptor knockout (using CD19‑Cre Insr^fl/fl) will recapitulate the aged phenotype: reduced SHM, skewed IgG glycosylation (↓ sialylation, ↑ galactose), and accelerated inflammaging markers (serum IL‑6, TNF‑α) despite youthful age.
   • Prediction: These mice exhibit comparable healthspan decline to wild‑type aged controls.
3. Pharmacologic enhancement of insulin signaling in aged B cells (e.g., low‑dose IGF‑1 or selective AKT activator) administered ex vivo or in vivo will increase phospho‑FOXO1, rescue AID expression, elevate SHM replacement mutations, and restore IgG sialylation to youthful levels, concomitant with reduced NF‑κB activity in splenic macrophages.
   • Prediction: Treated old mice display improved vaccine affinity maturation and extended median lifespan vs. vehicle.
4. Sex‑specific modulation: Male mice will exhibit a stronger link between insulin‑FOXO1 axis and SHM decline, aligning with reported sex‑biased SHM reduction tied to Phase II DNA repair.
   • Prediction: Male B cells show greater FOXO1 nuclear retention and more pronounced SHM loss than females under identical aging conditions.

Falsifiability

If any of the above measurements fail to show the predicted direction (e.g., insulin stimulation does not increase phospho‑FOXO1 or AID in aged B cells, or glycosylation remains unchanged), the hypothesis would be refuted, indicating that B‑cell‑intrinsic insulin signaling is not a primary driver of the observed SHM and inflammaging phenotypes.

Broader impact

Linking metabolic signaling to AID regulation offers a concrete node where interventions (IGF‑1 mimetics, FOXO1 inhibitors) could simultaneously improve antibody quality and curb inflammaging, addressing two hallmarks of aging with a single target.